Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > News > Celator(R) Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing

June 4th, 2007

Celator(R) Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing

Abstract:
Celator Pharmaceuticals announced positive safety and efficacy results from its Phase I study of CPX-1 (Irinotecan HCI:Floxuridine), Liposome Injection in patients with heavily pre-treated, advanced solid tumors. Results were presented yesterday in a poster presentation at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

CPX-1 is a combination therapy including irinotecan HCI and floxuridine, two approved and well known drug agents to treat cancer. The formulation of CPX-1 was developed based on ratiometric dosing using Celator's CombiPlex(TM) technology platform, a proprietary technology that identifies the optimal ratio of drugs to use in combination therapies and then incorporates an advanced nanoparticle delivery system to maintain those optimal ratios when drugs are administered and metabolized in patients. Pending regulatory approval, CPX-1 would be the first commercially-available combination therapy based on Celator's ratiometric dosing drug development platform.

Source:
earthtimes.org

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

New, old science combine to make faster medical test: Nanoparticles and Faraday rotation allow faster diagnoses January 23rd, 2017

New research helps to meet the challenges of nanotechnology: Research helps to make the most of nanoscale catalytic effects for nanotechnology January 20th, 2017

Chemists Cook up New Nanomaterial and Imaging Method: Nanomaterials can store all kinds of things, including energy, drugs and other cargo January 19th, 2017

'5-D protein fingerprinting' could give insights into Alzheimer's, Parkinson's January 19th, 2017

Announcements

Bruker Announces Acquisition of Nanoindenting Leader Hysitron: Acquisition strengthens Brukerís leading position in nanoanalysis and nanomechanical materials characterization January 24th, 2017

New low-cost technique converts bulk alloys to oxide nanowires January 24th, 2017

News from Quorum: Experienced electron microscopist, David McCarthy, talks about working with Quorum and his use of their coaters and cryo-SEM preparation instrumentation January 24th, 2017

Tough aqua material for water purification: Decontamination of water with a robust and sustainable membrane assembled from 2 synergistically working components January 24th, 2017

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project